EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-world experience in initiation of treatment with the selective cardiomyosin inhibitor mavacamten in an outpatient clinic cohort during the 12-week titration period

Finn Becker, Julia Novotny, Nadine Jansen, Sebastian Clauß, Florian Möller-Dyrna, Birge Specht, Madeleine Orban, Steffen Massberg, Stefan Kääb, Daniel Reichart

Clinical Research in Cardiology · 2026-05 · 115 (5) · 725-731

DOI: 10.1007/s00392-024-02544-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Research in Cardiology, online erschienen am 08.10.2024. Verfasst von Finn Becker und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine I, LMU University Hospital, LMU Munich, Marchioninistrasse 15, 81377, Munich, Germany. Hauptthemen laut MEDLINE: Cardiomyopathy, Hypertrophic, Aminobutyrates. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Klinikum der Universität München.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Lately, mavacamten emerged as a new therapeutic option for symptomatic patients with obstructive hypertrophic cardiomyopathy (oHCM). Clinical trials revealed reduction of serum biomarkers, and left ventricular outflow tract (LVOT) obstruction, as well as an improvement in clinical symptoms and exercise capacity. Nevertheless, clinical experience and manageability of patients in a real-world setting is still lacking. Material and methods 22 patients with symptomatic oHCM (54.5% male, age 58.5 ± 16.2 years) and elevated LVOT gradients were started on mavacamten between March 2023 and June 2024. All patients were New York Heart Association (NYHA) class II or higher. Seven patients were excluded from primary analysis due to comedication with Angiotensin-converting-enzyme-inhibitors or Angiotensin-II receptor blockers. Cardiac imaging, laboratory work-up and clinical evaluation were assessed at three visits during the 12 weeks initiation phase; Dosing of mavacamten was adjusted according to manufacturer’s recommendations.

Results

At 12 weeks, the majority of patients described a significant improvement of their quality of life. Work-up at 12 weeks revealed a significant reduction of serum biomarkers and LVOT gradients. In four patients, mavacamten needed to be temporarily paused due to clinical complaints or transient left ventricular ejection fraction deterioration below 50% with subsequent full recovery.

Conclusion

We provide first insights into the usage of mavacamten in oHCM patients during the titration period in a real-world setting. Clinical findings are in line with previous clinical trials. In accordance with current recommendations, we highlight the need for standardized follow-up of patients on mavacamten treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiomyopathy, HypertrophicAminobutyratesHumansMaleFemaleMiddle AgedTreatment OutcomeAgedQuality of LifeTime FactorsStroke VolumeBiphenyl CompoundsVentricular Function, LeftFollow-Up StudiesBenzylaminesUracil

Stichwörter der Autor:innen

Cardiomyosin inhibitorMavacamtenObstructive hypertrophic cardiomyopathy (oHCM)Titration periodTreatment

Substanzen

MYK-461AminobutyratesBiphenyl CompoundsBenzylaminesUracil

Autor:innen und Institutionen

  • Department of Medicine I, LMU University Hospital, LMU Munich, Marchioninistrasse 15, 81377, Munich, Germany.
  • DZHK (German Center for Cardiovascular Research), Partner Site Munich, Munich Heart Alliance (MHA), 80802, Munich, Germany.
  • Member of the European Reference Network for Rare, Low Prevalence and Complex Diseases of the Heart (ERN GUARD-Heart), Munich, Germany.
  • Institute of Surgical Research at the Walter-Brendel-Centre of Experimental Medicine University Hospital, LMU Munich, Munich, Germany.
  • Interfaculty Center for Endocrine and Cardiovascular Disease Network Modelling and Clinical Transfer (ICONLMU), LMU Munich, Munich, Germany.
  • Department of Medicine I, LMU University Hospital, LMU Munich, Marchioninistrasse 15, 81377, Munich, Germany. stefan.kaab@med.uni-muenchen.de.

Förderung

  • Klinikum der Universität München

Zitieren

APA

Becker, F., Novotny, J., Jansen, N., Clauß, S., Möller-Dyrna, F., Specht, B., Orban, M., Massberg, S., Kääb, S., & Reichart, D. (2026). Real-world experience in initiation of treatment with the selective cardiomyosin inhibitor mavacamten in an outpatient clinic cohort during the 12-week titration period. Clinical Research in Cardiology, 115(5), 725-731. https://doi.org/10.1007/s00392-024-02544-w

Vancouver

Becker F, Novotny J, Jansen N, Clauß S, Möller-Dyrna F, Specht B, et al. Real-world experience in initiation of treatment with the selective cardiomyosin inhibitor mavacamten in an outpatient clinic cohort during the 12-week titration period. Clinical Research in Cardiology. 2026;115(5):725-731. doi:10.1007/s00392-024-02544-w

BibTeX
@article{Becker2026,
  author = {Becker, Finn and Novotny, Julia and Jansen, Nadine and Clauß, Sebastian and Möller-Dyrna, Florian and Specht, Birge and Orban, Madeleine and Massberg, Steffen and Kääb, Stefan and Reichart, Daniel},
  title = {Real-world experience in initiation of treatment with the selective cardiomyosin inhibitor mavacamten in an outpatient clinic cohort during the 12-week titration period},
  journal = {Clinical Research in Cardiology},
  year = {2026},
  volume = {115},
  number = {5},
  pages = {725--731},
  doi = {10.1007/s00392-024-02544-w}
}
Kostenlos starten →